Forbes -- Pfizer has stopped entering new patients into the most advanced clinical trial of its experimental lung cancer drug because those who received it were more likely to suffer serious side effects and die.
Forbes -- Pfizer has stopped entering new patients into the most advanced clinical trial of its experimental lung cancer drug because those who received it were more likely to suffer serious side effects and die.
